BETH ISRAEL DEACONESS MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1896-01-01

Employees: -

Market Cap: -

Website: https://www.bidmc.org/

Clinical Trials

Gas Embolism With Use of Argon Plasma Coagulation

Completed

Conditions: Embolism, Air

First Posted Date: 2008-05-13

Last Posted Date: 2017-03-28

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 42

Registration Number: NCT00676858

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest

Phase 1

Completed

Conditions: Cardiac Arrest

Interventions: Drug: Hydrocortisone
Drug: Normal Saline

First Posted Date: 2008-05-13

Last Posted Date: 2017-05-17

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 50

Registration Number: NCT00676585

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Linkage Analysis in Interstitial Cystitis

Completed

Conditions: Urinary Bladder, Overactive
Painful Bladder Syndrome
Cystitis, Interstitial
Prostatitis
Chronic Pelvic Pain Syndrome

First Posted Date: 2008-05-09

Last Posted Date: 2017-02-03

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 300

Registration Number: NCT00675298

Locations: 🇺🇸
Jordan D Dimitrakoff, Boston, Massachusetts, United States

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Ketoconazole, Hydrocortisone and Dutasteride

First Posted Date: 2008-05-07

Last Posted Date: 2015-04-22

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 57

Registration Number: NCT00673127

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, Baltimore, Maryland, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 4 locations

Diagnostic Challenges in IC (and Male CPPS)

Completed

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Cystitis, Interstitial
Asymptomatic Inflammatory Prostatitis
Painful Bladder Syndrome
Chronic Bacterial Prostatitis

Interventions: Genetic: Genomic and proteomic biomarker discovery

First Posted Date: 2008-05-06

Last Posted Date: 2020-08-04

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 1000

Registration Number: NCT00672087

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

Phase 2

Completed

Conditions: MDS
AML
APLASTIC ANEMIA
MULTIPLE MYELOMA
MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
ALL
RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA
CML Chronic Phase, Accelerated Phase, or Blast Crisis
CLL

Interventions: Drug: Cyclophosphamide
Drug: fludarabine
Drug: cyclosporine
Drug: methotrexate
Biological: G-CSF

First Posted Date: 2008-03-17

Last Posted Date: 2017-04-06

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 25

Registration Number: NCT00636909

In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Biological: INKT
Drug: GM-CSF

First Posted Date: 2008-03-07

Last Posted Date: 2017-06-09

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 9

Registration Number: NCT00631072

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2008-02-29

Last Posted Date: 2017-03-28

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 20

Registration Number: NCT00626860

Locations: 🇺🇸
BIDMC, Boston, Massachusetts, United States

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

Phase 1

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2008-02-28

Last Posted Date: 2017-03-28

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 40

Registration Number: NCT00625755

Locations: 🇺🇸
BIDMC, Boston, Massachusetts, United States

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Biological: Dendritic Cell/Tumor Fusion Vaccine
Drug: Interleukin-12

First Posted Date: 2008-02-25

Last Posted Date: 2017-11-14

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 8

Registration Number: NCT00622401

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy